MAIN RESULTS OF NOXXON’S GLORIA PHASE 1/2 TRIAL OF NOX-A12 IN BRAIN CANCER TO BE PRESENTED AT ASCO 2022 ANNUAL MEETING
Berlin, Germany, 06 April 2022, 08:00 CEST – NOXXON Pharma SA (Euronext Growth Paris: ALNOX)a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that key data from the ongoing NOX-A12 Phase 1/2 GLORIA trial in brain cancer will be presented in a poster presentation at the 2022 American Annual Meeting of the Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois, USA, June 3-7, 2022.
ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. Its flagship event, the Annual Meeting, promotes cutting-edge research and attracts more than 40,000 oncology professionals from around the world each year.
The title of the abstract and details of the presentation by Dr. Frank Giordano, Principal Investigator of the GLORIA study and Director and Chairman of the Department of Radiation Oncology at University Hospital Bonn, Germany, will be made public by ASCO April 27, 2022 The full abstract will be available at ASCO.org/Abstracts and on the NOXXON website once the annual meeting abstracts are made public and the embargo is lifted, May 26, 2022 at 5:00 p.m. EDT .
To register for the event, please click here.
A copy of the presentation will be available atNOXXONit’s websiteshortly after the event.
For more information please contact:
NOXXON Pharma AG
Aram Mangasarian, Ph.D.
Managing Director Tel. +49 (0) 30 726247 0[email protected]
Investor and Media Relations:
Guillaume van Renterghem Tel. +41 (0) 76 735 01 31[email protected]
Phone. +33 (0)1 44 71 00 15[email protected]
NOXXON Oncology-The targeted pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXONThe approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and allow for greater therapeutic impact. by NOXXON the main program NOX-A12 provided the final front line data of a Keytruda® combined trial in patients with metastatic colorectal and pancreatic cancer published at the ESMO conference in September 2020 and in July 2021 the company announced its phase 2 study, OPTIMUS, to further evaluate the safety and efficacy of NOX-A12 in combination with Keytrud from Mercka® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in newly diagnosed brain cancer patients who will not clinically benefit from standard chemotherapy, provided frontline data from all three climbing cohorts of dose showing consistent tumor reductions and objective tumor responses. Additionally, GLORIA was expanded to assess the benefit of NOX-A12 with other treatment combinations, radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The companysecond ny clinic-the NOX-E36 active ingredient is a Phase 2 TME active ingredient targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at: www.noxxon.com.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
Visit NOXXON at LinkedIn and Twitter.
About the GLORIA study
GLORIA (NCT04121455) is the dose of NOXXON-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in front-line patients with partially resected or unresected glioblastoma (brain cancer) with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA is further evaluating the safety and efficacy of NOX-A12 in three additional arms combining NOX-A12 with: A. radiation therapy in patients with complete tumor resection; B. radiotherapy and bevacizumab in patients with incomplete tumor resection; and C. radiation therapy and pembrolizumab in patients with incomplete tumor resection.
About the OPTIMUS study
OPTIMUS (NCT04901741) is NOXXON’s open– two-arm phase 2 study of NOX-A12 in combination with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with stable microsatellite metastatic pancreatic cancer.
Translations of any press release into languages other than English are for the convenience of non-English speaking audiences only. The company has attempted to provide an accurate translation of the original English text, but due to nuances of translating into another language, slight differences may exist. Certain statements in this communication contain formulations or terms that refer to future or future developments, as well as negations of these formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication regarding expected or future results of business segments, financial indicators, changes in financial condition or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the current situation on the day of publication.